Insider Selling: Corbus Pharmaceuticals (NASDAQ:CRBP) Director Sells $15,680.00 in Stock

Key Points

• Director Yong Ben sold 2,000 Corbus Pharmaceuticals shares at an average price of $7.84, generating $15,680 and reducing his ownership by 17.57% to 9,383 shares.
• CRBP shares fell 14.4% to $6.92 during Tuesday trading, while the company reported a quarterly loss of $1.81 per share—$0.55 worse than analysts expected.
• Despite the recent weakness, analysts maintain a “Moderate Buy” consensus with a $41 price target, supported by promising early CRB-913 obesity-drug data; however, the program remains at the Phase 1b stage and carries substantial clinical and financial risks.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) Director Yong Ben sold 2,000 shares of the company's stock in a transaction on Monday, September 14th. The stock was sold at an average price of $7.84, for a total transaction of $15,680.00. Following the transaction, the director owned 9,383 shares of the company's stock, valued at $73,562.72. This represents a 17.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Corbus Pharmaceuticals Trading Down 14.4%

CRBP traded down $1.16 during midday trading on Tuesday, hitting $6.92. 3,747,824 shares of the company traded hands, compared to its average volume of 441,107. The business has a 50 day simple moving average of $9.75 and a two-hundred day simple moving average of $9.45. Corbus Pharmaceuticals Holdings, Inc. has a 52-week low of $6.32 and a 52-week high of $20.56. The company has a market capitalization of $129.20 million, a price-to-earnings ratio of -1.12 and a beta of 2.63.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.55). Equities research analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post -5.62 earnings per share for the current year.

Analyst Ratings Changes

• Corbus Pharmaceuticals NASDAQ: CRBP Gives a Bold Buy Signal

Several research firms recently commented on CRBP. Mizuho set a $33.00 price objective on Corbus Pharmaceuticals in a research note on Thursday, August 13th. Wedbush dropped their target price on shares of Corbus Pharmaceuticals from $38.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, May 27th. Guggenheim reiterated a "buy" rating on shares of Corbus Pharmaceuticals in a research report on Tuesday, May 26th. HC Wainwright reissued a "buy" rating and issued a $35.00 price target on shares of Corbus Pharmaceuticals in a research note on Monday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a research report on Friday, July 17th. Eight equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $41.00.

Institutional Trading of Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of CRBP. Engineers Gate Manager LP lifted its holdings in shares of Corbus Pharmaceuticals by 109.9% in the 2nd quarter. Engineers Gate Manager LP now owns 29,800 shares of the biopharmaceutical company's stock worth $280,000 after acquiring an additional 15,600 shares during the last quarter. Pale Fire Capital SE raised its holdings in shares of Corbus Pharmaceuticals by 13.8% in the 2nd quarter. Pale Fire Capital SE now owns 24,301 shares of the biopharmaceutical company's stock valued at $228,000 after buying an additional 2,951 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Corbus Pharmaceuticals in the 2nd quarter valued at $425,000. Seven Fleet Capital Management LP lifted its stake in Corbus Pharmaceuticals by 51.0% during the 1st quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company's stock worth $805,000 after acquiring an additional 28,937 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Corbus Pharmaceuticals by 53,592.3% during the 1st quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company's stock worth $131,000 after acquiring an additional 13,934 shares in the last quarter. 64.64% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Corbus Pharmaceuticals

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Promising CANYON-1 results: Daily oral CRB-913 produced statistically significant and clinically meaningful average weight loss of 5% at the 60-mg dose after 12 weeks, with no plateau observed. The drug was generally well tolerated, and its emerging gastrointestinal tolerability profile could help differentiate it from existing obesity therapies. Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study
• Positive Sentiment: Potential new obesity-drug class: Corbus said the findings support CRB-913’s potential as an oral, non-incretin weight-loss treatment. The data have also been selected for a late-breaking presentation at ObesityWeek 2026, increasing visibility for the program. Corbus Announces Positive Phase 1b Weight-Loss Data
• Positive Sentiment: Analyst support: HC Wainwright reaffirmed its “buy” rating and maintained a $35 price target, implying substantial upside if CRB-913 advances successfully through later-stage testing.
• Neutral Sentiment: Options activity signals heightened speculation: Traders purchased 7,228 call options Monday—about 523% above typical volume—before purchasing 10,124 put options Tuesday, roughly 690% above average. The sharp increase in both calls and puts reflects unusually high uncertainty and volatility rather than a clear consensus direction.
• Negative Sentiment: Early-stage and financial risks remain: CRB-913 has only generated Phase 1b topline data, so efficacy and safety must be confirmed in larger trials. Corbus also recently reported a wider-than-expected quarterly loss, while the stock’s decline from its 52-week high suggests investors may be taking profits or reassessing the initial enthusiasm.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company's lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body's innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.